{"result": "(\"entity\"<|>INTRALIPID<|>ORGANIZATION<|>Intralipid is a lipid emulsion used in parenteral nutrition, providing essential fatty acids and calories to patients who cannot receive oral nutrition.)\n##\n(\"entity\"<|>CLINOLEIC<|>ORGANIZATION<|>Clinoleic is a lipid emulsion used in pediatric parenteral nutrition, containing a blend of oils to meet the nutritional needs of patients.)\n##\n(\"entity\"<|>LIPOFUNDINA<|>ORGANIZATION<|>Lipofundina is a lipid emulsion used in parenteral nutrition, designed to provide essential fatty acids and energy to patients.)\n##\n(\"entity\"<|>LIPOPLUS<|>ORGANIZATION<|>Lipoplus is a lipid emulsion used in parenteral nutrition, formulated to provide a balanced source of fatty acids for patients.)\n##\n(\"entity\"<|>SMOFLIPID<|>ORGANIZATION<|>SMOFlipid is a lipid emulsion that combines different oils, including fish oil, used in parenteral nutrition to support patients' nutritional needs.)\n##\n(\"entity\"<|>TRIGLICÉRIDOS DE CADENA MEDIA<|>ORGANIZATION<|>Medium-chain triglycerides (MCT) are a type of fat used in some parenteral nutrition formulations to provide a quick source of energy.)\n##\n(\"entity\"<|>ÁCIDOS GRASOS ESENCIALES<|>ORGANIZATION<|>Essential fatty acids are fats that the body cannot produce on its own and must be obtained through diet or supplementation, crucial in parenteral nutrition.)\n##\n(\"entity\"<|>SÍNDROME DE INTESTINO CORTO<|>EVENT<|>Short bowel syndrome is a medical condition that occurs when a significant portion of the small intestine is missing or has been surgically removed, affecting nutrient absorption.)\n##\n(\"entity\"<|>COLSTASIS<|>EVENT<|>Cholestasis is a condition characterized by reduced or stopped bile flow, which can occur in patients receiving prolonged parenteral nutrition.)\n##\n(\"entity\"<|>FIBROSIS<|>EVENT<|>Fibrosis is the thickening and scarring of connective tissue, which can be a complication in patients with liver disease related to parenteral nutrition.)\n##\n(\"relationship\"<|>INTRALIPID<|>NUTRICIÓN PARENTERAL<|>Intralipid is a key component of parenteral nutrition, providing essential fats and calories to patients unable to eat orally.<|>9)\n##\n(\"relationship\"<|>CLINOLEIC<|>NUTRICIÓN PARENTERAL<|>Clinoleic is utilized in parenteral nutrition to meet the dietary needs of pediatric patients.<|>8)\n##\n(\"relationship\"<|>LIPOFUNDINA<|>NUTRICIÓN PARENTERAL<|>Lipofundina is included in parenteral nutrition formulations to supply necessary lipids to patients.<|>9)\n##\n(\"relationship\"<|>LIPOPLUS<|>NUTRICIÓN PARENTERAL<|>Lipoplus is used in parenteral nutrition to provide a balanced source of fatty acids for patients.<|>8)\n##\n(\"relationship\"<|>SMOFLIPID<|>NUTRICIÓN PARENTERAL<|>SMOFlipid is a lipid emulsion used in parenteral nutrition to support the nutritional needs of patients.<|>9)\n##\n(\"relationship\"<|>TRIGLICÉRIDOS DE CADENA MEDIA<|>NUTRICIÓN PARENTERAL<|>Medium-chain triglycerides are included in some parenteral nutrition formulations to provide a quick source of energy.<|>7)\n##\n(\"relationship\"<|>ÁCIDOS GRASOS ESENCIALES<|>NUTRICIÓN PARENTERAL<|>Essential fatty acids are critical in parenteral nutrition to prevent deficiencies in patients.<|>9)\n##\n(\"relationship\"<|>SÍNDROME DE INTESTINO CORTO<|>NUTRICIÓN PARENTERAL<|>Short bowel syndrome often requires parenteral nutrition for adequate nutrient absorption due to reduced intestinal length.<|>8)\n##\n(\"relationship\"<|>COLSTASIS<|>NUTRICIÓN PARENTERAL<|>Cholestasis can be a complication of prolonged parenteral nutrition, affecting liver function.<|>7)\n##\n(\"relationship\"<|>FIBROSIS<|>NUTRICIÓN PARENTERAL<|>Fibrosis can develop in patients with liver disease related to prolonged parenteral nutrition, indicating a serious health concern.<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ®) cuando se utilizan a corto plazo en neonatos o niños de mayor edad26. Se ha visto que en niños con nutrición parenteral prolongada, el uso de soluciones mixtas con aceite de pescado puede contribuir a proteger frente al desarrollo de colestasis26. Por último, la solución Omegaven®, a base únicamente de aceite de pescado, ha mostrado su eficacia en el tratamiento de rescate de pacientes con enfermedad hepática relacionada con la NP, especialmente en los afectos de síndrome de intestino corto27, 28, aunque la mejoría en la colestasis no siempre se asocia a menor progresión de la fibrosis29, 30. Hay que\n---\nTema 55. Nutrición parenteral en el paciente pediátrico: vías y fórmulas 867\n\n## Tabla 5. Emulsiones lipídicas disponibles en pediatría.\n\n| Componentes | Intralipid® (20%) | Clinoleic® (20%) | Lipofundina® (20%) | Lipoplus® (20%) | SMOFlipid® (20%) | Omegaven® (10%) |\n|-------------|-------------------|-------------------|---------------------|------------------|-------------------|-------------------|\n| Aceite de soja (%) | 100 | 20 | 50 | 40 | 30 | 0 |\n| TCM (%) | 0 | 0 | 50 | 50 | 30 | 0 |\n| Aceite de oliva (%) | 0 | 80 | 0 | 0 | 25 | 0 |\n| Aceite de pescado (%) | 0 | 0 | 0 | 10 | 15 | 100 |\n| Vitamina E (mg/l) | 38 | 32 | 85+/-20 | 190+/-30 | 200 | 150-296 |\n| Ácido linoleico (%) | 53 | 18,7 | 29,1 | 25,7 | 37,2 | 4,4 |\n| Ácido alfa-linolénico (%) | 8 | 2,3 | 4,5 | 3,4 | 4,7 | 1,8 |\n| EPA (%) | 0 | 0 | 0 | 3,7 | 4,7 | 19,2 |\n| DHA (%) | 0 | 0 | 0 | 2,5 | 4,4 | 12,1 |\n| Ratio n-6:n-3 | 7:1 | 9:1 | 7:1 | 2,7:1 | 2,5:1 | 1:8 |\n\nDHA: ácido docohexaenoico; EPA: ácido eicosapentaenoico; TCM: triglicéridos de cadena media.\n\ntener en cuenta que este tipo de solución no se puede utilizar de forma exclusiva en pacientes pediátricos durante un tiempo prolongado, por el riesgo asociado a desarrollar un déficit de ácidos grasos esenciales. Este riesgo podría no existir en caso de que el paciente reciba también alimentación por vía oral o enteral, pero eso aún está por determinar.\n\nLa carnitina es el transportador de los ácidos grasos de cadena larga al interior de la mitocondria para su oxidación. Tres cuartas partes de la carnitina proceden de la dieta. Las soluciones de NP no contienen habitualmente carnitina y, aunque los niveles plasmáticos están disminuidos en la mayoría de los pacientes con NP prolongada, su adición no mejora el aclaramiento lipídico en plasma ni previene la colestasis. En caso de considerar su inclusión en la bolsa de NP, las dosis utilizadas varían entre 5 y 30 mg/kg/día.\n\n### 5.3. Aminoácidos (AA)\n\nLas proteínas se suministran en forma de soluciones de aminoácidos (AA) y son esenciales para mantener la masa corporal magra. Su aporte debe minimizar el catabolismo proteico inducido por el estrés y el ayuno, y favorecer la síntesis proteica sin producir complicaciones hepáticas y/o renales. Los requerimientos proteicos se han establecido sobre las bases de una ingesta suficiente de energía, de tal forma que el esqueleto carbonado de los AA no sea necesario como fuente de energía; y de que la calidad de la proteína sea alta. Deben constituir entre el 12-16% del aporte calórico total (1 g = 4 kcal). Los aportes recomendados según la edad se señalan en la tabla 6.\n\nEn el RNPT es segura su utilización desde el primer día de vida con un aporte mínimo de 1,5 g/kg/día que evite el balance nitrogenado negativo³¹. La cantidad\n\n## Tabla 6. Requerimientos de aminoácidos en nutrición parenteral según edad.\n\n| Edad | Gramos/kg peso/día |  |\n|------|---------------------|------------------|\n|      | Límites | Recomendaciones |\n| Recién nacido pretérmino | 1,5-3,5 | 2,5-3,5 |\n| Recién nac\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>OMEGAVEN<|>ORGANIZATION<|>Omegaven is a solution based solely on fish oil, effective in treating patients with liver disease related to parenteral nutrition, especially in those affected by short bowel syndrome.)\n##\n(\"entity\"<|>NUTRICIÓN PARENTERAL<|>EVENT<|>Parenteral nutrition is a medical treatment involving the delivery of nutrients directly into the bloodstream, often used for patients who cannot eat by mouth.)\n##\n(\"entity\"<|>CARNITINA<|>PERSON<|>Carnitine is a transporter of long-chain fatty acids into the mitochondria for oxidation, essential for energy production in the body.)\n##\n(\"entity\"<|>DHA<|>ORGANIZATION<|>DHA, or docosahexaenoic acid, is an omega-3 fatty acid important for brain and eye health, often included in nutritional solutions.)\n##\n(\"entity\"<|>EPA<|>ORGANIZATION<|>EPA, or eicosapentaenoic acid, is an omega-3 fatty acid that has anti-inflammatory properties and is included in certain nutritional solutions.)\n##\n(\"entity\"<|>AMINOÁCIDOS<|>ORGANIZATION<|>Amino acids are essential nutrients supplied in parenteral nutrition to maintain lean body mass and support protein synthesis.)\n##\n(\"relationship\"<|>OMEGAVEN<|>NUTRICIÓN PARENTERAL<|>Omegaven is used in parenteral nutrition to treat liver disease in patients, indicating a direct application in this medical event.<|>8)\n##\n(\"relationship\"<|>CARNITINA<|>NUTRICIÓN PARENTERAL<|>Carnitine is relevant in parenteral nutrition as it helps transport fatty acids for energy production, which is crucial for patients receiving this treatment.<|>7)\n##\n(\"relationship\"<|>DHA<|>NUTRICIÓN PARENTERAL<|>DHA is included in nutritional solutions for parenteral nutrition, highlighting its importance in the dietary management of patients.<|>8)\n##\n(\"relationship\"<|>EPA<|>NUTRICIÓN PARENTERAL<|>EPA is also included in nutritional solutions for parenteral nutrition, emphasizing its role in patient care.<|>8)\n##\n(\"relationship\"<|>AMINOÁCIDOS<|>NUTRICIÓN PARENTERAL<|>Amino acids are a critical component of parenteral nutrition, necessary for maintaining body mass and supporting metabolic functions.<|>9)\n<|COMPLETE|>"}]}